ECM
ABUS icon

Eisler Capital Management’s Arbutus Biopharma ABUS Stock Holding History

Eisler Capital Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-123,200
Closed -$379K – 824
2025
Q2 		$379K Buy
123,200
+3,200
+3% +$10.6K ﹤0.01% 724
2025
Q1 		$422K Buy
+120,000
New +$400K ﹤0.01% 784

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Eisler Capital Management's ABUS Position: Q3 2025 in Review

Eisler Capital Management sold out of Arbutus Biopharma (ABUS) in Q3 2025, closing a stake of 276,375 shares — an estimated $851K sold.

Eisler Capital Management first reported a position in ABUS in Q1 2025 and held it in 2 quarters. The position peaked at $968K in Q1 2025. 166 funds tracked by Wall St. Rank hold ABUS as of Q3 2025.

  • Eisler Capital Management reported no remaining Arbutus Biopharma position as of Q3 2025 after selling out during the quarter.
  • Eisler Capital Management sold 276,375 Arbutus Biopharma shares in Q3 2025, an estimated $851K.
  • Eisler Capital Management first reported a position in Arbutus Biopharma in Q1 2025 and held it in 2 quarters.
  • Eisler Capital Management's Arbutus Biopharma position peaked at $968K in Q1 2025.
  • 166 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q3 2025.

Based on Eisler Capital Management's 13F filing for Q3 2025, filed 13 Nov 2025.